Bocci V, Pacini A, Pessina G P, Maioli E, Naldini A
Gen Pharmacol. 1987;18(4):343-6. doi: 10.1016/0306-3623(87)90088-7.
By intravenous (bolus) administration of human recombinant tumor necrosis factor (2.5 X 10(6) units) into rabbits and monkeys it has been possible to follow its decay in the plasma and to determine the pharmacokinetic parameters. After labelling TNF with 125I, simultaneous determination of protein-bound radioactivity and bioactivity was carried out with the result that radioactivity decays somewhat slower than bio-activity suggesting that the use of the former tracer alone may underestimate TNF catabolism. Simultaneous determination of 125I-TNF in rabbit plasma and lymph after intravenous and subcutaneous administration indicated a lymph to plasma TNF concentration ratio of about 0.1 and 1 or more for the two routes, respectively.
通过向兔和猴静脉（推注）给予重组人肿瘤坏死因子（2.5×10⁶单位），得以追踪其在血浆中的衰减情况并确定药代动力学参数。用¹²⁵I标记肿瘤坏死因子（TNF）后，同时测定了蛋白结合放射性和生物活性，结果放射性的衰减比生物活性稍慢，这表明仅使用前一种示踪剂可能会低估TNF的分解代谢。静脉和皮下给药后同时测定兔血浆和淋巴中的¹²⁵I-TNF，结果显示两条途径的淋巴与血浆TNF浓度比分别约为0.1和1或更高。
